Solazyme (SZYM) Q4 Results Uninspiring but Execution on Track - Goldman
Tweet Send to a Friend
Goldman Sachs today maintained a Buy rating on Solazyme (NASDAQ: SZYM) but trimmed its price target to $15.00 (from $17.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
